Prevalence and pattern of cognitive dysfunction in young adults and middle-aged patients with type-2 diabetes.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 40726648.
- Also identified by DOI 10.4103/jfmpc.jfmpc_1900_24 and PMC identifier 12296403.
- Licence recorded as CC BY-NC-SA.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
With the world's aging population, twin epidemics of type-2 diabetes (T2D) and dementia take a great toll on the healthcare burden. T2D carries a 2-3 times greater risk of developing cognitive impairment than controls. Early identification of cognitive impairment is important as it impairs diabetes self-management, making patients prone to complications. However, data about the assessment of cognitive impairment in T2D using a comprehensive cognitive battery is sparse in India. This study was undertaken to estimate the prevalence and pattern of cognitive impairment among young and middle-aged patients with T2D. A cross-sectional observational study was conducted in a tertiary care teaching hospital in Kolkata (2022-2024) among 125 Bengali-speaking T2D patients with formal education > class IV, aged between 20 and 60 years. The cognitive evaluation was done using the clinical dementia rating scale, mini-mental status examination (MMSE), Montreal cognitive assessment (MoCA), and Addenbrooke's cognitive examination (ACE)-III. Statistical analyses were done by Jeffrey's Amazing Statistics Program version 0.19 with appropriate tests (Chi-squared test, Mann-Whitney U test, Spearman correlation statistics, and logistic regression). <i>P</i> value < 0.05 was considered significant. T2D patients reported a more subjective sensation of forgetfulness compared to the control group (<i>P</i> = 0.001). MMSE was an insufficient screening tool to distinguish between these two groups. On MoCA and ACE-III, there was a significant difference in total scores between case and control groups (MoCA, <i>P</i> = 0.012 and ACE-III, <i>P</i> < 0.001). Based on ACE-III, 59.20% of T2D patients had cognitive impairment (<i>P</i> < 0.001). The odds of having cognitive impairment in T2D were 3.72 times higher than in the control group (<i>P</i> < 0.001). There was significant impairment of memory (<i>P</i> < 0.001), fluency (<i>P</i> = 0.020), and visuospatial ability (<i>P</i> = 0.032). Females (<i>P</i> = 0.010), less education (<i>P</i> < 0.001), lower socioeconomic status (<i>P</i> < 0.001), BMI < 23 kg/m<sup>2</sup> (<i>P</i> = 0.049), peripheral neuropathy (<i>P</i> = 0.001), hypothyroidism (<i>P</i> = 0.007), anxiety (<i>P</i> < 0.001), and depression (<i>P</i> < 0.001) were significantly associated with cognitive impairment in diabetes. This is the first study from Eastern India to use a comprehensive cognitive scale validated in the local vernacular. Cognitive impairment is prevalent among a significant portion of middle-aged, educated individuals with T2D. Cognitive evaluation should be incorporated into diabetes management from the onset, with a focus on addressing modifiable factors.